Impopharma Inc. Strengthens Management Team and Board of Directors

TORONTO, Oct. 5, 2017 /PRNewswire/ -- Impopharma Inc. today announced the following organizational changes:

• Named David Mayers as the Chief Operating Officer of the Company and appointed him to the Board of Directors, replacing Hanna Piskorz (co-founder), who has retired and will be stepping down from the Board
• Appointed Wayne Kreppner to the Board of Directors
• Hired Dr. David Brown as Senior Director of R&D, and
• Lloyd Segal will also be stepping down from the Board, having served as an independent Director. Impopharma's Executive Chairman and CEO Theron (Ted) Odlaug, Ph.D. stated that "we would like to thank both Hanna and Lloyd for their contributions to the organization and wish them both well in their future endeavors."

In his new role, Mr. Mayers will provide strategic leadership and assume responsibility for day-to-day operations of the organization. He brings 27 years of pharmaceutical experience; most recently as President and founder of Maycore Inc., a business development and consulting solutions company, and previously Managing Partner of Pharm Eng. Technologies. Prior to this, Mr. Mayers was President of WellSpring Pharma Services, where he managed strategic and operational aspects of the CDMO organization. Previously, Mr. Mayers was Vice President Manufacturing Operations at Purdue Pharma, where he managed significant facility expansions and engineered the launch and line extension of such major brands as Targin, Biphentin and OxyNEO. Mr. Mayers also has held leadership positions in Manufacturing, Quality, Research & Development, Operations, Project Management and Strategy for Apotex, Merck KGaA, Taro and SmithKline Beecham.

Mr. Mayers holds an Hons. BSc. Degree in Biological Sciences from the University of Guelph and an MBA from the Rotman School of Business, University of Toronto.

Dr. Odlaug, Impopharma's Executive Chairman, stated "David's extensive experience in the pharmaceutical industry, specifically in the areas of product development and analytical R&D coupled with his in-depth knowledge of the CDMO space make him the ideal person to help build out future."

David Brown joins Impopharma from Teva Ltd, where he was Director, R&D Program Management with responsibility for portfolio selection, project management and technical expertise. Previously, he was Director, Pharmaceutical Development. Dr. Brown began his career in the UK in respiratory drug development at Fisons Plc. After moving to Canada, he worked at RTP Pharma and Patheon Inc.

Dr. Brown holds an Hons. Bachelor of Pharmacy and a Ph.D. in Pharmaceutics from the School of Pharmacy, University of London, United Kingdom.

"We are pleased to announce, David Brown has assumed the role of Senior Director R&D overseeing all aspects of R&D including formulation, product development and analytical services," said Mr. Mayers. "Dr. Brown brings not only over 20 years of experience in project management and product development but his formulation experience in respiratory device products positions us well to serve our clients and develop future projects."

Wayne Kreppner was most recently President and Chief Operating Officer at Concordia International. Mr. Kreppner brings over 20 years of experience as a pharmaceutical operations and R&D executive. A co-founder and former Vice-President of Product Development at Trimel Pharmaceuticals, Mr. Kreppner was responsible for all scientific operations including R&D, clinical development, manufacturing and supply chain. From 1997 to 2008 Mr. Kreppner held various senior roles in operations and regulatory affairs with Biovail Corporation.

Mr. Kreppner holds a Hons. B.Sc. degree in Biochemistry from the University of Western Ontario, an M.Sc. in Medical Science from McMaster University and an MBA from the Ivey School of Business, University of Western Ontario.

Dr. Odlaug noted that "Wayne Kreppner brings a proven track record of experience in the pharmaceutical industry and will further enhance our strategic leadership as a member of our Board."

About Impopharma

Impopharma is a well-resourced development and testing facility with an expert and experienced team located in Concord, Ontario, Canada that specializes in the development and testing of pulmonary and nasal drug delivery systems and ophthalmic, otic, and dermal products. Please visit
www.Impopharma.com.

Contact:
Impopharma Inc.
Vice President, Finance
Tel: (905) 760-0232
Vien Brewster

SOURCE Impopharma Inc.